AR125589A1 - Métodos para el tratamiento de la enfermedad ocular tiroidea - Google Patents
Métodos para el tratamiento de la enfermedad ocular tiroideaInfo
- Publication number
- AR125589A1 AR125589A1 ARP220100468A ARP220100468A AR125589A1 AR 125589 A1 AR125589 A1 AR 125589A1 AR P220100468 A ARP220100468 A AR P220100468A AR P220100468 A ARP220100468 A AR P220100468A AR 125589 A1 AR125589 A1 AR 125589A1
- Authority
- AR
- Argentina
- Prior art keywords
- mutation
- replace
- methods
- antibody
- kabat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156320P | 2021-03-03 | 2021-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125589A1 true AR125589A1 (es) | 2023-08-02 |
Family
ID=83154512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100468A AR125589A1 (es) | 2021-03-03 | 2022-03-02 | Métodos para el tratamiento de la enfermedad ocular tiroidea |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240158516A1 (https=) |
| EP (1) | EP4301410A4 (https=) |
| JP (1) | JP2024510142A (https=) |
| CN (1) | CN117813114A (https=) |
| AR (1) | AR125589A1 (https=) |
| AU (1) | AU2022230416A1 (https=) |
| BR (1) | BR112023017797A2 (https=) |
| CA (1) | CA3210855A1 (https=) |
| CO (1) | CO2023012639A2 (https=) |
| MX (1) | MX2023010278A (https=) |
| TW (1) | TW202246339A (https=) |
| WO (1) | WO2022187510A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| EP4384219A4 (en) | 2021-08-10 | 2025-06-18 | Viridian Therapeutics, Inc. | COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE |
| US20230406942A1 (en) * | 2022-06-10 | 2023-12-21 | Horizon Therapeutics Ireland Dac | Igf1r antibodies |
| WO2024069236A1 (en) * | 2022-09-30 | 2024-04-04 | Horizon Therapeutics Ireland Dac | Methods for treating inactive or chronic thyroid eye disease |
| AU2024287547A1 (en) * | 2023-07-07 | 2026-01-22 | Viridian Therapeutics, Inc. | Methods of treating chronic thyroid eye disease |
| WO2026055673A1 (en) * | 2024-09-09 | 2026-03-12 | Viridian Therapeutics, Inc. | Methods for treatment of thyroid eye disease with an anti-igf-1r antibody |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3146469B2 (ja) * | 1993-09-03 | 2001-03-19 | 株式会社ニッショー | 自動注射器 |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| MX2013008833A (es) * | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
| MX364861B (es) * | 2013-04-29 | 2019-05-09 | Hoffmann La Roche | Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares. |
| HRP20260151T1 (hr) * | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
-
2022
- 2022-02-25 TW TW111107147A patent/TW202246339A/zh unknown
- 2022-03-02 AR ARP220100468A patent/AR125589A1/es unknown
- 2022-03-03 US US18/548,484 patent/US20240158516A1/en active Pending
- 2022-03-03 MX MX2023010278A patent/MX2023010278A/es unknown
- 2022-03-03 EP EP22764068.7A patent/EP4301410A4/en active Pending
- 2022-03-03 AU AU2022230416A patent/AU2022230416A1/en active Pending
- 2022-03-03 BR BR112023017797A patent/BR112023017797A2/pt not_active Application Discontinuation
- 2022-03-03 CN CN202280031787.0A patent/CN117813114A/zh active Pending
- 2022-03-03 CA CA3210855A patent/CA3210855A1/en active Pending
- 2022-03-03 JP JP2023553957A patent/JP2024510142A/ja active Pending
- 2022-03-03 WO PCT/US2022/018737 patent/WO2022187510A1/en not_active Ceased
-
2023
- 2023-09-25 CO CONC2023/0012639A patent/CO2023012639A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023017797A2 (pt) | 2023-11-21 |
| WO2022187510A1 (en) | 2022-09-09 |
| EP4301410A4 (en) | 2025-03-26 |
| CN117813114A (zh) | 2024-04-02 |
| TW202246339A (zh) | 2022-12-01 |
| CA3210855A1 (en) | 2022-09-09 |
| EP4301410A1 (en) | 2024-01-10 |
| CO2023012639A2 (es) | 2023-10-09 |
| MX2023010278A (es) | 2023-11-21 |
| AU2022230416A1 (en) | 2023-09-28 |
| AU2022230416A9 (en) | 2024-01-25 |
| US20240158516A1 (en) | 2024-05-16 |
| JP2024510142A (ja) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125589A1 (es) | Métodos para el tratamiento de la enfermedad ocular tiroidea | |
| AU2017225111B2 (en) | Modified antibody regions and uses thereof | |
| RU2534347C1 (ru) | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| JP2017113028A5 (https=) | ||
| RU2015130100A (ru) | TNF-альфа антиген-связывающие белки | |
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| AU2017214251A1 (en) | Bispecific T cell engaging antibody constructs | |
| CN115340608A (zh) | 用于癌症治疗的抗pd-1和抗-lag3抗体 | |
| US10954292B2 (en) | Anti-PACAP antibody | |
| AU2014227664A1 (en) | Dual specific binding proteins directed against TNFalpha | |
| WO2013101972A2 (en) | Dual variable domain immunoglobulins and uses thereof | |
| JP2013543384A5 (https=) | ||
| CL2020002621A1 (es) | Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso | |
| PE20221585A1 (es) | Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla-4) y uso del mismo | |
| CN105358575B (zh) | 干扰素α和ω抗体拮抗剂 | |
| PE20220489A1 (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso | |
| AU2018280679A1 (en) | Novel anti-HSA antibodies | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| PY24114686A (es) | Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente al ligando 1A (TL1A) similar al TNF, y uso del mismo | |
| AR122480A1 (es) | VARIANTE DE LA Fc Y PREPARACIÓN DE LA MISMA | |
| CN116547002A (zh) | Il-7结合蛋白及其在医学疗法中的用途 | |
| AR132867A1 (es) | Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a axl, y uso del mismo | |
| JP2025533112A (ja) | Ｇｐｒｃ５ｄ ｔｃｂとｃｄ３８抗体との併用療法 | |
| AR129553A1 (es) | Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a bcma, y uso del mismo |